This is a preview of subscription content, log in via an institution to check access.
Reference
Yao Y, et al. Cost-effectiveness of adding dapagliflozin to standard treatment for heart failure with reduced ejection fraction patients in China. ESC heart failure : 27 Oct 2020. Available from: URL: https://doi.org/10.1002/ehf2.12844
Rights and permissions
About this article
Cite this article
Dapagliflozin is cost effective for HF with reduced ejection fraction in China. PharmacoEcon Outcomes News 866, 9 (2020). https://doi.org/10.1007/s40274-020-7269-4
Published:
Issue Date:
DOI: https://doi.org/10.1007/s40274-020-7269-4